Messer Laurel H, Forlenza Gregory P, Gonder-Frederick Linda, Hood Korey, Ebekozien Osagie, Barnard-Kelly Katharine, Laffel Lori M, Sherr Jennifer L, Lal Rayhan, Weinzimer Stuart A
Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Tandem Diabetes Care, San Diego, CA, USA.
J Diabetes Sci Technol. 2025 Jul;19(4):950-957. doi: 10.1177/19322968251335971. Epub 2025 Jul 1.
The technological progress to date with automated insulin delivery (AID) has ushered in a new era of challenges and opportunities for people with diabetes (PWD), spotlighting implementation considerations. Beyond physiologic and technologic variation, cost, access, and health care professional (HCP) endorsement/experience lead to uneven uptake of AID technologies and attenuate universal ease of use. For AID to be broadly implemented, we must prioritize the lived experience for PWD and consider how to alleviate burden to promote physical/functional health, psychological well-being, and social well-being. Expectations and education help HCPs and PWD navigate the similarities and differences between AID devices, and help find common ties: users need to give the system time to work, learn to trust it, and not try to "trick" the system. Despite these learnings, disparities in uptake exist, both in clinical trials and in routine clinical care. Strategies to proactively address AID disparities must be enacted at multiple levels, including recognizing HCP biases, using clinic-based benchmarking efforts, and addressing insurance and policy barriers, all of which increase in importance as AID becomes more common for people with type 2 diabetes. Furthermore, broader implementation will require comprehensive health care system integration efforts, including new data solutions. Overall, the success of AID requires ongoing transformation of clinical paradigms, with lockstep alignment between PWD and their families, health care professionals, researchers, funders, policy makers, and industry partners.
迄今为止,自动胰岛素输送(AID)技术的进步为糖尿病患者(PWD)带来了一个充满挑战与机遇的新时代,突出了实施方面的考量。除了生理和技术差异外,成本、可及性以及医疗保健专业人员(HCP)的认可/经验导致AID技术的采用不均衡,并削弱了普遍的易用性。为了广泛实施AID,我们必须优先考虑PWD的实际生活体验,并思考如何减轻负担以促进身体/功能健康、心理健康和社会福祉。期望和教育有助于HCP和PWD了解AID设备之间的异同,并找到共同之处:用户需要给系统时间来发挥作用,学会信任它,而不是试图“欺骗”系统。尽管有这些经验教训,但在临床试验和常规临床护理中,采用情况仍存在差异。必须在多个层面制定积极应对AID差异的策略,包括认识到HCP的偏见、利用基于诊所的基准评估工作以及解决保险和政策障碍,随着AID在2型糖尿病患者中变得更加普遍,所有这些因素的重要性都在增加。此外,更广泛的实施将需要全面的医疗保健系统整合努力,包括新的数据解决方案。总体而言,AID的成功需要临床范式的持续转变,PWD及其家人、医疗保健专业人员、研究人员、资助者、政策制定者和行业合作伙伴要步调一致。